Iteos Therapeutics Valuation
| ITOS Stock | USD 7.07 0.09 1.29% |
At this time, the firm appears to be undervalued. Iteos Therapeutics retains a regular Real Value of $7.42 per share. The prevalent price of the firm is $7.07. Our model calculates the value of Iteos Therapeutics from evaluating the firm fundamentals such as Return On Equity of -0.2, shares outstanding of 36.53 M, and Return On Asset of -0.13 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Iteos Therapeutics' valuation include:
Price Book 0.4037 | Enterprise Value | Enterprise Value Ebitda 0.4956 | Price Sales 7.3798 | Forward PE 12.5628 |
Undervalued
Today
Please note that Iteos Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Iteos Therapeutics is based on 3 months time horizon. Increasing Iteos Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Iteos stock is determined by what a typical buyer is willing to pay for full or partial control of Iteos Therapeutics. Since Iteos Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iteos Stock. However, Iteos Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.07 | Real 7.42 | Target 25.0 | Hype 7.07 | Naive 7.31 |
The intrinsic value of Iteos Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Iteos Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Iteos Therapeutics helps investors to forecast how Iteos stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iteos Therapeutics more accurately as focusing exclusively on Iteos Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Iteos Therapeutics' intrinsic value based on its ongoing forecasts of Iteos Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Iteos Therapeutics' closest peers.
Iteos Therapeutics Cash |
|
Iteos Valuation Trend
Iteos Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Iteos Therapeutics' financial worth over time. Using both Iteos Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Iteos Therapeutics Total Value Analysis
Iteos Therapeutics is currently estimated to have valuation of (224.89 M) with market capitalization of 258.29 M, debt of 6.06 M, and cash on hands of 791.86 M. The negative valuation of Iteos Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Iteos Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(224.89 M) | 258.29 M | 6.06 M | 791.86 M |
Iteos Therapeutics Investor Information
About 95.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 3.18. The entity had not issued any dividends in recent years. Based on the key indicators related to Iteos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Iteos Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Iteos Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Iteos Therapeutics has an asset utilization ratio of 1.89 percent. This implies that the Company is making $0.0189 for each dollar of assets. An increasing asset utilization means that Iteos Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Iteos Therapeutics Ownership Allocation
Iteos Therapeutics has a total of 36.53 Million outstanding shares. The majority of Iteos Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Iteos Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Iteos Therapeutics. Please pay attention to any change in the institutional holdings of Iteos Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Iteos Therapeutics Profitability Analysis
The company reported the previous year's revenue of 12.6 M. Net Loss for the year was (112.64 M) with profit before overhead, payroll, taxes, and interest of 35 M.About Iteos Therapeutics Valuation
The stock valuation mechanism determines Iteos Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Iteos Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Iteos Therapeutics. We calculate exposure to Iteos Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Iteos Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 13.5 M | 12.8 M | |
| Pretax Profit Margin | (9.96) | (9.46) | |
| Operating Profit Margin | (13.80) | (13.11) | |
| Net Loss | (10.28) | (9.77) | |
| Gross Profit Margin | 0.93 | 1.07 |
Iteos Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Iteos Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 35.8 M | |
| Quarterly Earnings Growth Y O Y | -0.886 | |
| Forward Price Earnings | 12.5628 |
Iteos Therapeutics Current Valuation Indicators
Iteos Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Iteos Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Iteos Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Iteos Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Iteos Therapeutics' worth.Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.